M
Matthew J. Armstrong
Researcher at Queen Elizabeth Hospital Birmingham
Publications - 165
Citations - 7088
Matthew J. Armstrong is an academic researcher from Queen Elizabeth Hospital Birmingham. The author has contributed to research in topics: Fatty liver & Medicine. The author has an hindex of 34, co-authored 137 publications receiving 4988 citations. Previous affiliations of Matthew J. Armstrong include National Health Service & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
Matthew J. Armstrong,Matthew J. Armstrong,Piers Gaunt,Guruprasad P. Aithal,Darren Barton,Darren Barton,Diana Hull,Diana Hull,Richard D. Parker,Richard D. Parker,Jonathan Hazlehurst,Kathy Guo,Kathy Guo,G. Abouda,M. Aldersley,Deborah D. Stocken,Stephen C. L. Gough,Jeremy W. Tomlinson,Rachel M. Brown,Stefan G. Hübscher,Stefan G. Hübscher,Philip N. Newsome,Philip N. Newsome +22 more
TL;DR: Liraglutide was safe, well tolerated, and led to histological resolution of non-alcoholic steatohepatitis, warranting extensive, longer-term studies.
Journal ArticleDOI
Association of Non-Alcoholic Fatty Liver Disease With Chronic Kidney Disease: A Systematic Review and Meta-Analysis
Giovanni Musso,Roberto Gambino,James H. Tabibian,Mattias Ekstedt,Stergios Kechagias,Masahide Hamaguchi,Rolf Hultcrantz,Hannes Hagström,Seung Kew Yoon,Phunchai Charatcharoenwitthaya,Jacob George,Francisco Barrera,Svanhildur Hafliðadóttir,Einar Björnsson,Matthew J. Armstrong,Laurence J. Hopkins,Xin Gao,Sven Francque,An Verrijken,Yusuf Yilmaz,Keith D. Lindor,Michael Charlton,Robin Haring,Markus M. Lerch,Rainer Rettig,Henry Völzke,Seungho Ryu,Guolin Li,Linda L. Wong,Mariana V. Machado,Helena Cortez-Pinto,Kohichiroh Yasui,Maurizio Cassader +32 more
TL;DR: In a systematic review and meta-analysis, Giovanni Musso and colleagues examine the association between non-alcoholic fatty liver disease and chronic kidney disease and finds no clear link between the two.
Journal ArticleDOI
Extrahepatic complications of nonalcoholic fatty liver disease.
TL;DR: The cumulative evidence to date suggests that individuals with NAFLD (specifically, nonalcoholic steatohepatitis) harbor an increased and independent risk of developing CVD, T2DM, CKD, and colorectal neoplasms.
Journal ArticleDOI
Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study.
Thomas Marjot,Andrew M. Moon,Jonathan Cook,Sherief Abd-Elsalam,Costica Aloman,Matthew J. Armstrong,Elisa Pose,Erica J. Brenner,Tamsin Cargill,Maria-Andreea Catana,Renumathy Dhanasekaran,Ahad Eshraghian,Ignacio García-Juárez,Upkar S. Gill,Patricia D. Jones,James Kennedy,Aileen Marshall,Charmaine Matthews,George F. Mells,Carolyn Mercer,Ponni V. Perumalswami,Emma Avitabile,Xialong Qi,Feng Su,Nneka N. Ufere,Yu Jun Wong,Ming-Hua Zheng,Eleanor Barnes,Alfred S. Barritt,Gwilym J. Webb,Gwilym J. Webb +30 more
TL;DR: It is demonstrated that baseline liver disease stage and ALD are independent risk factor for death from COVID-19, which is the largest reported cohort of CLD and cirrhosis patients with SARS-CoV-2 infection to date.
Journal ArticleDOI
Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort.
Matthew J. Armstrong,Diarmaid D. Houlihan,Diarmaid D. Houlihan,L Bentham,Jean C. Shaw,R Cramb,Simon Olliff,Paramjit Gill,James Neuberger,Richard J. Lilford,Philip N. Newsome,Philip N. Newsome +11 more
TL;DR: In this paper, the authors calculated the range of disease severity of non-alcoholic fatty liver disease (NAFLD) in a primary care setting and found that NAFLD is the commonest cause of incidental LFT abnormalities in primary care.